Cagrilintide · research summary

New Drugs on the Block: Dietary Management and Nutritional Considerations During the Use of Anti-Obesity Medication.

Nutrients · 2026. Summary drawn from the study's full text. Each statement is followed by the exact sentence it comes from. This is a research summary, not medical advice.

Study type

Narrative review
“For this narrative review, a comprehensive search was conducted using a combination of MeSH terms and free-text keywords at the PubMed and clinicaltrials.gov databases.”

Subjects

Individuals with obesity and type 2 diabetes using incretin-based pharmacotherapy
“The present review synthesizes the available evidence on GI AEs associated with incretin-based therapies and examines whether structured, targeted nutritional management can meaningfully reduce symptom burden.”

Reported findings

Gastrointestinal adverse events are the principal barrier to long-term adherence, with up to 80% of treated individuals experiencing some degree of intolerance.
“The GI tract is the organ system most frequently affected by AEs associated with GLP-1 RA therapy, with reports indicating that up to 80% of treated individuals may experience some degree of intolerance, regardless of the severity.”
Conventional calorie deficit models in major trials were insufficient to fully address medication-related intolerance, as GI adverse events remained the predominant cause of treatment discontinuation.
“This recurring observation implies that conventional calorie deficit models, even when intensive, may not sufficiently accommodate the unique physiological consequences of GLP-1/GIP RAs.”
Incretin-based therapies are associated with reductions in lean body mass and increased risks of osteoporosis or fragility fractures.
“Both SEM and TZP have been associated with a higher risk of osteoporosis, or fragility fractures.”

Limitations stated by the authors

Many randomized controlled trials lack granular data on specific GI symptom attribution to withdrawal and do not utilize standardized, mechanism-oriented dietary protocols tailored to the physiological effects of the drugs.
“First, while GI AEs are consistently described as the principal drivers of treatment discontinuation, many RCTs do not provide granular data specifying the exact proportion of withdrawals directly attributable to individual GI symptoms.”

Source: PubMed 41901137 · DOI 10.3390/nu18060962 · all study summaries

Reported findings

Gastrointestinal adverse events are the principal barrier to long-term adherence, with up to 80% of treated individuals experiencing some degree of intolerance.

“The GI tract is the organ system most frequently affected by AEs associated with GLP-1 RA therapy, with reports indicating that up to 80% of treated individuals may experience some degree of intolerance, regardless of the severity.”

Conventional calorie deficit models in major trials were insufficient to fully address medication-related intolerance, as GI adverse events remained the predominant cause of treatment discontinuation.

“This recurring observation implies that conventional calorie deficit models, even when intensive, may not sufficiently accommodate the unique physiological consequences of GLP-1/GIP RAs.”

Incretin-based therapies are associated with reductions in lean body mass and increased risks of osteoporosis or fragility fractures.

“Both SEM and TZP have been associated with a higher risk of osteoporosis, or fragility fractures.”

Limitations stated by the authors

Many randomized controlled trials lack granular data on specific GI symptom attribution to withdrawal and do not utilize standardized, mechanism-oriented dietary protocols tailored to the physiological effects of the drugs.

“First, while GI AEs are consistently described as the principal drivers of treatment discontinuation, many RCTs do not provide granular data specifying the exact proportion of withdrawals directly attributable to individual GI symptoms.”